Загрузка...
Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
BACKGROUND: The aim of the study was to investigate the temporary combination of anti-PD-1 plus targeted therapy followed by single targeted therapy in advanced renal cell carcinoma (RCC) as second-line therapy. METHODS: A total of 17 patients from Fudan University Shanghai Cancer Center (FUSCC) wit...
Сохранить в:
| Опубликовано в: : | Transl Androl Urol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AME Publishing Company
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8185682/ https://ncbi.nlm.nih.gov/pubmed/34159088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tau-21-338 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|